ERBE-ELEKTROMEDIZIN
6.4.2021 13:02:09 CEST | Business Wire | Press release
An investment to strengthen our operating room presence
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210406005418/en/
“This acquisition reflects our determination to become a solution provider for surgeries and procedures where visualization is critical. We will offer holistic solutions, from visualization to therapy. Entering into the world of fluorescence imaging systems is the logical first step to provide the required added value to our customers", according to Christian O. Erbe, CEO & President at Erbe Elektromedizin GmbH. Maxer’s highly innovative product portfolio combined with Erbe’s energy-emitting high-tech products will allow existing unmet user needs to be addressed.
Better vision makes better surgery
Maxer’s prime innovation focus is on the development of high-end visualization. The technology delivers bright and pin-sharp multi-spectral images for NIR fluorescence-guided surgery and regular white light images. Now, Erbe will be able to offer best-in-class performance with 4K and fluorescence-guided systems in endoscopy as well as for open surgeries.
In 2020, Maxer and its partners, the Ludwig Maximilian University (LMU) Munich and the Technical University Munich (TUM), won the first prize of the German Medical Award in the “Innovation Product” category for its Atlas project. The plan is to provide the surgeon with a “GPS system” that enables the performance of advanced laparoscopic surgeries with increased surgical precision. This will help to reduce complications and risks during oncological surgeries and increase quality of patient life.
A perfect match with excellent growth prospects
The philosophy and values at Maxer are similar to Erbe’s. The company has a remarkable track record of high-tech devices in the last seven years and is perfectly positioned to master future opportunities, such as augmented reality-guided surgery. A broad minimal invasive instrument portfolio will be an ideal match to Erbe’s existing offering.
“Wonderful instruments and multi-spectral imaging systems will get access to the market through our strong sales force and our distribution partners in more than 110 countries”, says Marcus C. Felstead, CMO at Erbe.
“This acquisition will allow the company to speed up delivery of breakthrough innovations in areas of image-guided surgery,” states Shirish Joshi, Managing Director at Maxer.
Erbe was advised by ConAlliance (Mergers & Acquisitions) and RWT Reutlingen (Legal and Financial).
Our vision
The combination of electrosurgery and imaging will provide added value by processing and combining data using AI. This will lead to new treatment options and enhance patient safety. The best of both worlds.
About Maxer
Located in the Tuttlingen medical endoscopy cluster in Germany, Maxer is specialized in minimally invasive surgery (MIS). Maxer manufactures a wide range of endoscopic systems and instruments for laparoscopy, hysteroscopy, urology, pediatric surgery, arthroscopy, spine endoscopy and ENT surgery. Maxer’s core strength has been in the development of top-of-the-line visualization technologies. Maxer is partnering with the Ludwig Maximilian University (LMU) Munich and the Technical University Munich (TUM) to bring computer-assisted surgery to operating rooms.
About Erbe
Erbe Elektromedizin GmbH develops, manufactures and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OP teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryosurgery
An international network
- 15 subsidiaries in Europe, America and Asia
- 1 representative office
- Erbe is active in 110 national markets
The Erbe workforce
- Over 1,000 employees worldwide
- Some 700 of them in Germany
Erbe Elektromedizin GmbH
Waldhoernlestr. 17,
72072 Tuebingen, Germany
http://www.erbe-med.com
info@erbe-med.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005418/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom